Liminatus Pharma, Inc.
LIMN
$0.18
$0.00-2.17%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -187.81% | 44.53% | 77.65% | -80.64% | 10.76% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -- | -- | -- | -- |
| Change in Net Operating Assets | -433.33% | -396.34% | -371.03% | 114.87% | 86.91% |
| Cash from Operations | -586.60% | -496.37% | -345.57% | -46.87% | 49.14% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 72.81% | 52.15% | 8.37% | -247.99% | -247.99% |
| Cash from Investing | 77.80% | 61.43% | 29.61% | -87.62% | -333.46% |
| Total Debt Issued | 10.63% | 9.02% | 32.49% | 70.12% | 35.00% |
| Total Debt Repaid | -- | -550.00% | -407.81% | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -6,921.39% | -- | -- |
| Cash from Financing | 116.88% | 110.00% | 135.36% | 22.06% | 635.47% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 135.80% | 276.71% | 330.69% | -129.15% | 82.99% |